<DOC>
	<DOC>NCT02683317</DOC>
	<brief_summary>The purpose of this study is to evaluate whether docosahexaenoic acid given by enteral feeding prevent retinopathy of prematurity and/or diminish its severity in preterm infants.</brief_summary>
	<brief_title>Enteral Administration of Docosahexaenoic Acid to Prevent Retinopathy of Prematurity</brief_title>
	<detailed_description>Preterm neonates who start receiving enteral feeding will receive the intervention with docosahexaenoic acid (DHA) since the first day and throughout 14 days, one dose per day. The opthalmic evaluation will be done after 4-5 weeks after birth and followed until 42-45 corrected gestational age.</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy of Prematurity</mesh_term>
	<criteria>Birth weight &lt; 1500 g Plan to feed by enteral way at a short term Written informed consent, signed by both parents. Congenital malformations that avoid enteral feeding immunosuppressor diseases Need for major surgery Persistent bleeding at any level Mother taking n3 supplements and planning to breastfed Parents who decline the authorization for participating in the study Early discharge to other hospital outside the metropolitan area</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Weeks</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>DHA</keyword>
	<keyword>Retinopathy of Prematurity</keyword>
</DOC>